Univerza v Ljubljani, Fakulteta za farmacijo, Aškerčeva 7, 1000 Ljubljana, Slovenia.
Univerza v Ljubljani, Fakulteta za farmacijo, Aškerčeva 7, 1000 Ljubljana, Slovenia.
Int J Pharm. 2018 Sep 5;548(1):263-275. doi: 10.1016/j.ijpharm.2018.06.065. Epub 2018 Jun 30.
The purpose of this study was to develop self-microemulsifying (SME-) tablets to improve resveratrol solubility whilst delivering resveratrol in a preferred tablet dosage form. Resveratrol was dissolved in liquid self-microemulsifying drug delivery system (SMEDDS) (10% w/w) and solidified through adsorption on several different solid carriers. Two ranges of synthetic amorphous silica (Sylysia® 290, 350, 470, 580; Syloid® 244FP, AL-1FP) as well as granulated magnesium aluminometasilicate (Neusilin® US2) were screened for their SMEDDS adsorbent capacity. The most efficient carrier from every range was chosen for further SME-tablet development. To counteract the high ratio of liquid in SME-tablets, additional dry binders (microcrystalline cellulose, copovidone) were added to the tableting mixture, as well as superdisintegrant (croscarmellose sodium) and lubricant (magnesium stearate). Finally, approx. 600 mg tablets were directly pressed using 12 mm flat face punch, containing 41.75% SMEDDS. Overall, all tablets exhibited sufficient hardness (>50 N), although it was negatively affected by higher compression force. Tablets with Neusilin® US2 proved to have highest hardness, as granulated structure of Neusilin® US2 provided best compaction properties needed for successful direct compression of tablets. All prepared SME tablet formulations disintegrated in under 10 min and formed microemulsions (droplet size < 100 nm) upon dilution with water, with Neusilin® US2 tablets exhibiting the lowest droplet size (<30 nm). While conventional dissolution test indicated incomplete resveratrol release from solid carriers in both pH 1.2 and 6.8 media, no difference fatty acid amount titrated during fasted state in vitro lipolysis between liquid and solid SMEDDS was observed. Moreover, accelerated stability tests confirmed over 90% of trans-resveratrol remained in solid SMEDDS following 90 days at 40 °C, with no crystallization of resveratrol observed during that time. To sum up, through adsorption on solid carriers, in particular Neusilin® US2, SMEDDS was successfully transformed into a directly compressible mixture and tableted without the loss of its self-microemulsifying ability.
本研究旨在开发自微乳(SME-)片剂,以提高白藜芦醇的溶解度,同时以首选的片剂剂量形式递送白藜芦醇。白藜芦醇溶解在液体自微乳药物递送系统(SMEDDS)(10%w/w)中,并通过吸附在几种不同的固体载体上固化。两种范围的合成无定形二氧化硅(Sylysia®290、350、470、580;Syloid®244FP、AL-1FP)以及颗粒状镁铝硅酸盐(Neusilin®US2)被筛选用于其 SMEDDS 吸附能力。从每个范围内选择最有效的载体用于进一步的 SME 片剂开发。为了抵消 SME 片剂中液体的高比例,向压片混合物中添加了额外的干粘合剂(微晶纤维素、共聚维酮)以及超级崩解剂(交联羧甲基纤维素钠)和润滑剂(硬脂酸镁)。最后,使用 12mm 平冲头直接压制约 600mg 片剂,其中包含 41.75%SMEDDS。总体而言,所有片剂均表现出足够的硬度(>50N),尽管较高的压缩力会产生负面影响。含有 Neusilin®US2 的片剂具有最高的硬度,因为 Neusilin®US2 的颗粒状结构提供了成功直接压制片剂所需的最佳压缩性能。所有制备的 SME 片剂配方在不到 10 分钟内崩解,并在用水稀释时形成微乳液(粒径<100nm),其中 Neusilin®US2 片剂的粒径最低(<30nm)。虽然常规溶解试验表明在 pH1.2 和 6.8 介质中,固体载体不能完全释放白藜芦醇,但在空腹状态下体外脂肪分解过程中,液体和固体 SMEDDS 滴定的脂肪酸量没有差异。此外,加速稳定性试验证实,在 40°C 下放置 90 天后,超过 90%的反式白藜芦醇仍保留在固体 SMEDDS 中,在此期间未观察到白藜芦醇结晶。总之,通过吸附在固体载体上,特别是 Neusilin®US2,SMEDDS 成功地转化为可直接压缩的混合物并压制成片剂,而不会失去其自微乳能力。